Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Verve Therapeutics Inc Logo

Combined Holdings of Verve Therapeutics (VERV) - Updated Daily

Maxinomics.com icon
YouTube Logo
Date
Direction
Shares
Fund Weight
Fund
September 23, 2022
BUY596.547k0.2823%ARKK
September 23, 2022
BUY78.511k0.1162%ARKG
September 22, 2022
BUY63.751k0.0286%ARKK
September 22, 2022
BUY8.211k0.0117%ARKG
September 21, 2022
BUY21.983k0.0099%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$24
⚖️Weighting🧢Market Cap
0.6%$1.48b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
321591.49
💳ARK Estimated Cost Average🌏Country
$37.81 - ARKG$35.37 - ARKK
🇺🇸United States
🎫ARK Ownership Percent
5.44%
Description
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.
Website
www.vervetx.com

Research Notes and Commentary for VERV

No Research Notes Found for VERV